Your Web Site
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of...
Celgene International Sarl (NASDAQ: CELG) announced that its oral cancer drug REVLIMID (lenalidomide) has received marketing authorization approval from Health Canada for use in combination with dexamethasone as a treatment for...
